Squarepoint
GPCR icon

Squarepoint’s Structure Therapeutics GPCR Stock Holding History

Squarepoint’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Buy
+22,646
New +$1.55M ﹤0.01% 2706
2025
Q3 		– Sell
-15,176
Closed -$315K – 4592
2025
Q2 		$315K Buy
+15,176
New +$334K ﹤0.01% 3645
2024
Q4 		– Sell
-5,163
Closed -$227K – 5194
2024
Q3 		$227K Sell
5,163
-9,286
-64% -$359K ﹤0.01% 3616
2024
Q2 		$567K Buy
14,449
+617
+4% +$25.3K ﹤0.01% 2984
2024
Q1 		$593K Buy
+13,832
New +$583K ﹤0.01% 2935

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Squarepoint's GPCR Position: Q1 2026 in Review

Squarepoint opened a new position in Structure Therapeutics (GPCR) in Q1 2026: 22,646 shares worth $1.09M. The stake represents ﹤0.01% of the portfolio and ranks #2706 among its holdings. This is a return to the name: Squarepoint previously reported a position in GPCR as recently as Q2 2025.

Squarepoint first reported a position in GPCR in Q1 2024 and has held it in 5 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Squarepoint held 22,646 shares of Structure Therapeutics worth $1.09M as of Q1 2026.
  • Structure Therapeutics was a new Squarepoint position in Q1 2026.
  • Structure Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2706 holding.
  • Squarepoint first reported a position in Structure Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.